(Q24203727)

https://api.crossref.org/works/10.1002%2F14651858.CD009318.PUB2

Lacosamide in painful diabetic neuropathy: an 18-week double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009318.PUB2

Efficacy and safety of lacosamide in diabetic neuropathic pain: an 18-week double-blind placebo-controlled trial of fixed-dose regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009318.PUB2

Efficacy and safety of lacosamide in painful diabetic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009318.PUB2

Long-term oral lacosamide in painful diabetic neuropathy: a two-year open-label extension trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009318.PUB2

Lacosamide: a review of preclinical properties.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009318.PUB2

Phenytoin for neuropathic pain and fibromyalgia in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009318.PUB2

Prevalence of chronic pain with neuropathic characteristics in the general population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009318.PUB2

Clonazepam for neuropathic pain and fibromyalgia in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009318.PUB2

Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009318.PUB2

Recommendations for the pharmacological management of neuropathic pain: an overview and literature update

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009318.PUB2

The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009318.PUB2

Valproic acid and sodium valproate for neuropathic pain and fibromyalgia in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009318.PUB2

Prevalence of self-reported neuropathic pain and impact on quality of life: a prospective representative survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009318.PUB2

Epidemiology and treatment of neuropathic pain: the UK primary care perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009318.PUB2

Primary care incidence and treatment of four neuropathic pain conditions: a descriptive study, 2002-2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009318.PUB2

Lacosamide: an adjunctive agent for partial-onset seizures and potential therapy for neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009318.PUB2

Pharmacology and treatment of neuropathic pains

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009318.PUB2

Missing data handling in chronic pain trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009318.PUB2

Meta-analysis in clinical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009318.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009318.PUB2

Using numerical results from systematic reviews in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009318.PUB2

Size is everything--large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009318.PUB2

Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009318.PUB2

Pregabalin for acute and chronic pain in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009318.PUB2

"Evidence" in chronic pain--establishing best practice in the reporting of systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009318.PUB2

Numbers-needed-to-treat analyses--do timing, dropouts, and outcome matter? Pooled analysis of two randomized, placebo-controlled chronic low back pain trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009318.PUB2

Fibromyalgia: Moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009318.PUB2

Gabapentin for chronic neuropathic pain and fibromyalgia in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009318.PUB2

Minimum efficacy criteria for comparisons between treatments using individual patient meta-analysis of acute pain trials: examples of etoricoxib, paracetamol, ibuprofen, and ibuprofen/paracetamol combinations after third molar extraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009318.PUB2

Mean analgesic consumption is inappropriate for testing analgesic efficacy in post-operative pain: analysis and alternative suggestion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009318.PUB2

Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009318.PUB2

LOCF approach to handling missing data overestimates the pain score improvement of drop-outs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009318.PUB2

Gray matter volumes of pain-related brain areas are decreased in fibromyalgia syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009318.PUB2

Antidepressants for neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009318.PUB2

Differential block of sensory neuronal voltage-gated sodium channels by lacosamide [(2R)-2-(acetylamino)-N-benzyl-3-methoxypropanamide], lidocaine, and carbamazepine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009318.PUB2

Enriched enrollment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009318.PUB2

Pregabalin in fibromyalgia--responder analysis from individual patient data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009318.PUB2

Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009318.PUB2

The Epidemiology of Chronic Pain of Predominantly Neuropathic Origin. Results From a General Population Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009318.PUB2

Anticonvulsant drugs for acute and chronic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009318.PUB2

Carbamazepine for acute and chronic pain in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009318.PUB2

Lamotrigine for acute and chronic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009318.PUB2

The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009318.PUB2

The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009318.PUB2

A new definition of neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009318.PUB2

Antinociceptive efficacy of lacosamide in a rat model for painful diabetic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009318.PUB2

inferred from DOI database lookup

7 January 2021

based on heuristic

Patient-centered perspective on treatment outcomes in chronic pain

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009318.PUB2

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/14651858.CD009318.PUB2

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

22336864

1 reference

Consolidated OpenCitations Corpus – April 2017